stockrowQIAGEN N.V.
QGEN Healthcare Diagnostics & Research
QIAGEN N.V.’s revenue for fiscal 2025 (year ended December 2025) was $2.1 billion, up 5.65% from fiscal 2024.
- Revenue
- +0.28%
- EPS
- +7.94%
- Free cash flow
- +30.5%
- Total debt
- +13.8%
Quarter to June 2026, against a year earlier
Follow QGEN
Alert me
QIAGEN N.V. (QGEN) Operating cash flow
QIAGEN N.V.'s operating cash flow for fiscal 2025 was $654.3M, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $654.5M. Over the past ten years it has ranged from $286.8M (fiscal 2017) to $715.3M (fiscal 2022); the current reading is higher than 82% of that period. QIAGEN N.V. ranks 13th of 49 Diagnostics & Research companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $654.3M | (2.85%) |
| FY2024 | $673.6M | 46.60% |
| FY2023 | $459.5M | (35.76%) |
| FY2022 | $715.3M | 11.93% |
| FY2021 | $639.0M | 39.58% |
| FY2020 | $457.8M | 38.38% |
| FY2019 | $330.8M | (7.97%) |
| FY2018 | $359.5M | 25.36% |
| FY2017 | $286.8M | (16.05%) |
| FY2016 | $341.6M | 7.59% |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Jun 2026 | $200.7M | 99.44% |
| Mar 2026 | $100.6M | (46.51%) |
| Dec 2025 | $188.1M | 14.01% |
| Sep 2025 | $165.0M | 2.22% |
| 42 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| ICLR ICON PLC compare | $1.0B |
| MEDP Medpace Holdings, Inc. compare | $723.0M |
| RVTY Revvity Inc. compare | $655.8M |
| QGEN QIAGEN N.V. | $654.5M |
| CRL Charles River Laboratories International, Inc. compare | $622.4M |
| RDNT RadNet, Inc. compare | $310.1M |
| BLLN BillionToOne, Inc. compare | $47.9M |
| GH Guardant Health, Inc. compare | −$173.5M |
| GRAL GRAIL, Inc. compare | −$306.2M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on QGEN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement